[HTML][HTML] Genomic mechanisms influencing outcome in chronic myeloid leukemia
A Fernandes, N Shanmuganathan, S Branford - Cancers, 2022 - mdpi.com
Simple Summary Chronic myeloid leukemia (CML) is a blood cancer currently well
managed with drugs that inhibit the protein responsible for the disease. However, some …
managed with drugs that inhibit the protein responsible for the disease. However, some …
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia
A Fernandes, N Shanmuganathan, S Branford - Cancers, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
Genomic mechanisms influencing outcome in chronic myeloid leukemia
A Fernandes, N Shanmuganathan, S Branford - 2022 - digital.library.adelaide.edu.au
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.
A Fernandes, N Shanmuganathan, S Branford - Cancers, 2022 - europepmc.org
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
[PDF][PDF] Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia. Cancers 2022, 14, 620
A Fernandes, N Shanmuganathan, S Branford - 2022 - core.ac.uk
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
[HTML][HTML] Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia
A Fernandes, N Shanmuganathan, S Branford - Cancers, 2022 - ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
Genomic mechanisms influencing outcome in chronic myeloid leukemia
A Fernandes, N Shanmuganathan, S Branford - 2022 - hekyll.services.adelaide.edu.au
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia
A Fernandes, N Shanmuganathan, S Branford - Cancers, 2022 - search.proquest.com
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia
A Fernandes, N Shanmuganathan, S Branford - Cancers, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.
A Fernandes, N Shanmuganathan, S Branford - Cancers, 2022 - europepmc.org
Chronic myeloid leukemia (CML) represents the disease prototype of genetically based
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …
diagnosis and management. Tyrosine kinase inhibitors (TKIs), that target the causal BCR …